A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Trial Profile

A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Epstein-Barr virus-specific T-cell therapy Atara/MSKCC (Primary)
  • Indications Lymphoproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 10 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
    • 10 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jan 2018.
    • 03 Jan 2017 According to an Atara Biotherapeutics media release, the Company plans to submit in 2018 an application for Conditional Marketing Authorization Approval of ATA 129 in the treatment of patients with rituximab refractory EBV-PTLD following hematopoietic cell transplant (HCT). The Conditional MAA will be based on data from phase I and II studies and supported by available data from the pase III studies in rituximab refractory EBV-PTLD after HCT and solid organ transplantation (SOT).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top